Literature DB >> 22978537

Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.

Daniel Orringer1, Darryl Lau, Sameer Khatri, Grettel J Zamora-Berridi, Kathy Zhang, Chris Wu, Neeraj Chaudhary, Oren Sagher.   

Abstract

OBJECT: The extent of resection (EOR) is a known prognostic factor in patients with glioblastoma. However, gross-total resection (GTR) is not always achieved. Understanding the factors that prevent GTR is helpful in surgical planning and when counseling patients. The goal of this study was to identify demographic, tumor-related, and technical factors that influence EOR and to define the relationship between the surgeon's impression of EOR and radiographically determined EOR.
METHODS: The authors performed a retrospective review of the electronic medical records to identify all patients who underwent craniotomy for glioblastoma resection between 2006 and 2009 and who had both preoperative and postoperative MRI studies. Forty-six patients were identified and were included in the study. Image analysis software (FIJI) was used to perform volumetric analysis of tumor size and EOR based on preoperative and postoperative MRI. Using multivariate analysis, the authors assessed factors associated with EOR and residual tumor volume. Perception of resectability was described using bivariate statistics, and survival was described using the log-rank test and Kaplan-Meier curves.
RESULTS: The EOR was less for tumors in eloquent areas (p = 0.014) and those touching ventricles (p = 0.031). Left parietal tumors had significantly greater residual volume (p = 0.042). The average EOR was 91.0% in this series. There was MRI-demonstrable residual tumor in 69.6% of cases (16 of 23) in which GTR was perceived by the surgeon. Expert reviewers agreed that GTR could be safely achieved in 37.0% of patients (17 of 46) in this series. Among patients with safely resectable tumors, radiographically complete resection was achieved in 23.5% of patients (4 of 17). An EOR greater than 90% was associated with a significantly greater 1-year survival (76.5%) than an EOR less than 90% (p = 0.005).
CONCLUSIONS: The authors' findings confirm that tumor location affects EOR and suggest that EOR may also be influenced by the surgeon's ability to judge the presence of residual tumor during surgery. The surgeon's ability to judge completeness of resection during surgery is commonly inaccurate. The authors' study confirms the impact of EOR on 1-year survival.

Entities:  

Mesh:

Year:  2012        PMID: 22978537     DOI: 10.3171/2012.8.JNS12234

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  75 in total

1.  The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience.

Authors:  Sameah A Haider; Seokchun Lim; Steven N Kalkanis; Ian Y Lee
Journal:  J Neurooncol       Date:  2018-12-01       Impact factor: 4.130

2.  Fluorescence in a cryptococcoma following administration of 5-aminolevulinic acid hydrochloride (Gliolan).

Authors:  Waldo Gerard Solis; Mitchell Hansen
Journal:  BMJ Case Rep       Date:  2017-04-11

3.  Fluorescein-Guided Surgery for Pediatric Brainstem Gliomas: Preliminary Study and Technical Notes.

Authors:  Zhan Xue; Lu Kong; Chang-Cun Pan; Zhen Wu; Jun-Ting Zhang; Li-Wei Zhang
Journal:  J Neurol Surg B Skull Base       Date:  2018-06-25

4.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

5.  Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected].

Authors:  Elena Rampazzo; Alessandro Della Puppa; Chiara Frasson; Giusy Battilana; Sara Bianco; Renato Scienza; Giuseppe Basso; Luca Persano
Journal:  J Neurooncol       Date:  2014-01-09       Impact factor: 4.130

6.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

Review 7.  Improving the accuracy of brain tumor surgery via Raman-based technology.

Authors:  Todd Hollon; Spencer Lewis; Christian W Freudiger; X Sunney Xie; Daniel A Orringer
Journal:  Neurosurg Focus       Date:  2016-03       Impact factor: 4.047

8.  Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.

Authors:  Benjamin B Kasten; Ke Jiang; Denzel Cole; Aditi Jani; Neha Udayakumar; G Yancey Gillespie; Guolan Lu; Tingting Dai; Eben L Rosenthal; James M Markert; Jianghong Rao; Jason M Warram
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

9.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

10.  Combined fluorescence-guided surgery and photodynamic therapy for glioblastoma multiforme using cyanine and chlorin nanocluster.

Authors:  Clare W Teng; Ahmad Amirshaghaghi; Steve S Cho; Shuting S Cai; Emma De Ravin; Yash Singh; Joann Miller; Saad Sheikh; Edward Delikatny; Zhiliang Cheng; Theresa M Busch; Jay F Dorsey; Sunil Singhal; Andrew Tsourkas; John Y K Lee
Journal:  J Neurooncol       Date:  2020-09-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.